Compare Cassava Sciences Inc (FLNA) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs VNET Group Inc — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while VNET Group Inc trades at $7.72 (market cap $2.25B). The key difference: VNET Group Inc is far larger — about 42.3× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.
| FLNA | VNET | |
|---|---|---|
Market Cap | $53.14M | $2.25B |
Sector | Health | Technology |
52-Week High | $4.64 | $14.03 |
52-Week Low | $1.09 | $7.34 |
Enterprise Value | -$33.43M | $5.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
VNET Group trades at $7.77, up 0.26% with a bearish technical outlook. The company reported a Q1 2026 net loss of $1.20 per share, missing estimates, though revenue grew to $390.13 million. Despite negative profitability margins, analyst sentiment is positive with a 62.5% buy rating and a 54% upside price target. Recent news highlights strategic AI investments and a class action settlement.
The outlook is mixed; strong AI-driven demand and new ownership provide growth catalysts, but persistent losses and high debt pose significant risks. Investors should weigh the potential for operational turnaround against financial instability and legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
